Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $2.15, but opened at $2.05. Autolus Therapeutics shares last traded at $2.12, with a volume of 439,481 shares.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday. Wells Fargo & Company reduced their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Finally, Truist Financial reduced their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Trading Down 1.4%

The firm has a market capitalization of $564.22 million, a price-to-earnings ratio of -1.75 and a beta of 1.76. The company has a fifty day moving average price of $1.55 and a 200-day moving average price of $1.95.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. As a group, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Virtus ETF Advisers LLC boosted its position in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares during the period. Daiwa Securities Group Inc. boosted its position in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares during the period. Barclays PLC boosted its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares during the period. Jane Street Group LLC bought a new stake in Autolus Therapeutics during the fourth quarter worth approximately $26,000. Finally, Invesco Ltd. boosted its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the period. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.